NNC6022-0001 / Novo Nordisk - LARVOL DELTA

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People (clinicaltrials.gov) - P1 | N=56 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Metabolic Disorders

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People (clinicaltrials.gov) - P1 | N=56 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2024 ➔ Mar 2025 | Trial primary completion date: Oct 2024 ➔ Mar 2025

Enrollment closed • Trial completion date • Trial primary completion date • Metabolic Disorders

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Metabolic Disorders

A Study to See How Safe a New Medicine (NNC6022-0001) is in Healthy People (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Novo Nordisk A/S

New P1 trial • Metabolic Disorders